Study of Marstacimab in Men With Hemophilia

A Multicenter, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous or Intravenous PF-06741086 in Subjects With Severe Hemophilia

Category & Conditions:
Rare Diseases
Medicine:
marstacimab (PF-06741086)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B7841002
Open Plain Language Summary Result:Click here